Exabis Library
Welcome to the e-CCO Library!
P515: Infliximab desensitization in patients with Inflammatory Bowel Diseases: a safe therapeutic alternative
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P515: Manipulating the microbiome in paediatric acute severe colitis with a cocktail of antibiotics: A pilot randomised controlled trial
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P516 Daily consumers of drip-filtered coffee have a decreased risk of developing late-onset Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P516: Adrenal suppression in inflammatory bowel disease patients treated with glucocorticoids: a systematic review
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P516: Discrete choice experiment to examine patient preferences for surgical interventions in patients with Crohn’s perianal fistulas: results from a global burden of illness study
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P516: Efficacy and safety of tofacitinib retreatment for ulcerative colitis after treatment interruption: Results from the OCTAVE clinical trials
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P516: Humoral immune responses to SARS-CoV-2 vaccines in an ozanimod open-label extension study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P516: Serological biomarkers of tissue remodeling are associated with endoscopic remission in Crohn’s disease patients treated with GED-0301 (mongersen)
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P516: The use of first-line biologics in patients with ulcerative colitis in Norway from 2011 to 2016
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P517 A randomised, placebo-controlled pilot trial of faecal microbiota transplantation for paediatric Crohn’s disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P517: Activity assessment in ulcerative colitis: correlation analysis of endoscopic and histological scores
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P517: Features of cytomegalovirus infection in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P517: One year effectiveness and safety of ustekinumab in Ulcerative Colitis: a multicentre real-world study from Italy.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P517: Re-treatment with filgotinib in patients with Ulcerative Colitis following treatment interruption: Analysis of the SELECTION and SELECTIONLTE studies
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM
P517: The effects and adherence of Asacol® comparing 2.4 g once daily with 800 mg three times or 1200 mg twice daily for maintain therapy in the ulcerative colitis: Prospective multicentre randomised study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P517: Ustekinumab monitoring levels predict the need for intensification in patients with inflammatory bowel disease.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P518 Ulcerative colitis drug development success rates are higher than the industry average
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P518: Cardiovascular Risk Factors in Adolescents with inflammatory bowel disease: A Cross-sectional Population-Based Study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P518: Compliance with Faecal calprotectin home testing as standard during COVID-19 pandemic compared to laboratory based testing pre-COVID.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P518: Partial enteral nutrition use for Crohn’s disease management: a systematic review
2022
ECCO'22
Friday, 11 February 2022, 3:56 PM